Drug intelligence / Profile preview

VVD-130850 + pembrolizumab

Development stage: Unknown
Lead developer: Vividion Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

VVD-130850 + pembrolizumab is a combination therapy being investigated for the treatment of advanced solid and hematologic tumors. VVD-130850 is an oral small molecule inhibitor of STAT3 that binds to a novel allosteric pocket, leading to direct inhibition of DNA binding and expression of STAT3 target genes in cancer cells without affecting STAT3 protein levels. Pembrolizumab (Keytruda) is a humanized monoclonal anti-PD1 antibody that blocks the interaction between PD-1 and its ligands (PDL1 and PDL2), releasing PD-1 pathway-mediated inhibition of the immune response and improving anti-tumor immunity.

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on VVD-130850 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VVD-130850 + pembrolizumab.

Explore the full profile